FDA approves Merck vaccine

Order byBest matchMost fresh

Novavax scores narrower Covid vaccine approval

FDA approves Novavax COVID vaccine with new conditions

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House of Representatives try to overcome internal divisions about cuts to the Medicaid health program and tax breaks in high-cost coastal states.

· 1d · on MSN

FDA Changes How COVID Vaccines Will Be Approved—Here’s What To Know

WebMD · 1d

FDA Approves Novavax COVID Vaccine With Restricted Use

· 1d

F.D.A. Poised to Restrict Access to Covid Vaccines

The Food and Drug Administration will permit Covid vaccines for adults over 65 and those with certain medical conditions in the fall, according to new regulatory standards detailed on Tuesday by agen...

· 1d

FDA tightens requirements for COVID vaccine, adding trials for healthy adults

· 1d

Annual COVID-19 Shots For Healthy Younger Adults, Children Will No Longer Be Routinely Approved

· 1d

FDA may limit future Covid-19 shots to older people and those at risk of serious infection

Millions of healthy adults and kids will likely lose access to updated vaccines under the new criteria.

· 12h

FDA plans to limit COVID vaccine to only high-risk people. Who would still be eligible?

· 1d

FDA sets new COVID booster guidelines for healthy adults under 65

The Washington Post7d

FDA to issue new vaccine approval guidance amid questions over coronavirus shots

Send in your questions here. End of carousel The FDA was on track to grant full approval for the vaccine April 1, according to two people familiar with the matter who spoke on the condition of ...

FDA limits access to COVID-19 vaccine to older adults and other high-risk groups – a public health expert explains the new rules

The FDA’s decision to adopt a risk-based framework for the COVID-19 vaccine aligns with the expected recommendations from the Advisory Committee on Immunization Practices, an ad

Trending on Bing

Novavax scores narrower Covid vaccine approval